NS Pharma gains EC orphan drug designation to treat EGPA
NS Pharma has received orphan drug designation from the European Commission for NS-229 for eosinophilic granulomatosis with polyangiitis.
NS Pharma has received orphan drug designation from the European Commission for NS-229 for eosinophilic granulomatosis with polyangiitis.
What's Your Reaction?
